Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 179 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DOXY Clear all
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 30, 2026, 3:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lefamulin for M. Genitalium Treatment Failures

NCT05111002
View directory record Official record
Conditions
Mycoplasma Genitalium Infection
Interventions
Lefamulin, Doxycycline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT04128176
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Rituximab combined with Omalizumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 1 Interventional

Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?

NCT05001750
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Ventriculitis, Cerebral, Hydrocephalus
Interventions
Long term (continuous) prophylactic antibiotics, 24 hours antibiotics
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

NCT01426269
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 30, 2026, 3:16 PM EDT
Withdrawn Phase 2 Interventional

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

NCT04433078
View directory record Official record
Conditions
Cytokine Storm, SARS-CoV-2
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

NCT07544251
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline, Doxycycline
Drug
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
9 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg

NCT00647959
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Tablets, 150mg, Adoxa Tablets 150 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150
View directory record Official record
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 30, 2026, 3:16 PM EDT
Completed No phase listed Observational

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy

NCT00917553
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
doxycycline monohydrate, Placebo
Drug
Lead sponsor
Thomas Gardner
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 3 Interventional

Effects of Low-Dose Doxycycline on Oral Bone Loss

NCT00066027
View directory record Official record
Conditions
Periodontitis
Interventions
20 mg doxycycline hyclate, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Lincoln, Nebraska • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 30, 2026, 3:16 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

NCT02036528
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Gentamicin Topical Gel, Ciprofloxacin, Doxycycline
Drug
Lead sponsor
Royer Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 30, 2026, 3:16 PM EDT
Active, not recruiting Phase 1 Interventional

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

NCT03435952
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract
Interventions
Pembrolizumab, Clostridium Novyi-NT, Doxycycline
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

NCT00829764
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Monohydrate
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 2 Interventional

Daily Doxycycline for Early Syphillis

NCT06683638
View directory record Official record
Conditions
Syphilis
Interventions
Doxycycline 200mg daily for 14 days
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

NCT02829060
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions
Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Withdrawn Phase 4 Interventional

Doxycycline Outcomes in Lupus Erythematosus

NCT01014260
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Placebo, Doxycycline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 30, 2026, 3:16 PM EDT
Terminated Phase 3 Interventional Results available

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

NCT03558984
View directory record Official record
Conditions
Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions
D-PLEX, Standard of Care
Drug · Other
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Huston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Continuous Oral Contraceptives and Doxycycline

NCT00480532
View directory record Official record
Conditions
Contraceptives, Oral
Interventions
Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 30, 2026, 3:16 PM EDT
Terminated Phase 2 Interventional

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

NCT02341209
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Interventions
Doxycycline monohydrate
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 30, 2026, 3:16 PM EDT